Medical companies are braced for a series of costly settlements this year over actions brought by US agencies for alleged bribery and aggressive marketing practices overseas, even as they seek to raise ethical standards and improve self regulation around the globe.
Pfizer is close to a deal with the Department of Justice concerning “potentially improper payments” outside the US, while probes are also under way against drug companies including GlaxoSmithKline, Merck, Baxter, BMS, Eli Lilly, AstraZeneca and Smith & Nephew.
via ft.com
No comments:
Post a Comment